Objective： The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy, Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or...Objective： The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy, Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemotherapy may improve both disease free survival （DFS） and overall survival （OS） of naive patients, but its role in the second-line therapy for relapsed non-Hodgkin＇s Lymphoma （NHL） remains to be defined, This study aimed to evaluate the efficacy of rituximab-containing salvage regimens for relapsed or refractory NHL, and observe the toxicities. Methods： The clinical data of 54 patients, who were with relapsed or refractory NHL and treated in the Cancer Center of Sun Yat-sen University, were analyzed retrospectively, Of the 54 patients, 29 were man, 25 were women, with a median age of 52.5 years old （range 18 to 75）; 50 patients （92.6%） scored 0-1 for the ECOG performance status; for second-line international prognostic index （slPI）, 21 （38.9%） scored 0-1,30 （55.6%） scored 2 to 3, and 3 （5.6%） scored 4-5; 40 cases were diffuse large B-cell lymphoma （DLBCL）, accounting for 74.1% of all subtypes, Rituximab was administered intravenously at a dose of 375 mg/m^2 at the day before each chemotherapy cycle, The second or third-line salvage regimens included EPOCH, CHOP, DHAP, DICE, IVAC, IMVP-16 and FND, Results： Of the 54 patients, 49 received retuximab-containing salvage regimens, The objective response rate of the 45 evaluable cases was 68,8%, with a complete remission （CR） rate of 37.7%; 3 patients achieved CR after radiotherapy following rituximab-based regimens and 3 achieved CR after autologous hematopoietic stem cell transplantation, The most frequent adverse events were leucopenia, nausea and alopecia. The addition of rituximab to chemotherapy only elevated the occurrence of mild infusion-related reactions, such as chills, fever and pruritus. The median follow-up time was 18 months （range 2-86 months）; 5 patients were lost, 24 were dead （23 died of lymphoma, and 1 died of severe hepatitis）, the other patients remained alive. The median survival time was 32 months （range 2-86 months, 95% confidential interval 16-48 months）. The 1-, 2- and 3-year OS rates were 70.6%, 53,6% and 41,5%, respectively, The median TTP was 6 months （range 0-52 months）, The median PFS was 10 months （range 0-47 months, 95% CI 0-26 months）, The 1- and 2-year PFS were 49,3% and 41,3%. Conclusion： Rituximab-containing salvage regimens are effective and well tolerated therapy for patients with relapsed or refractory B-cell NHL, even those were extensively treated.展开更多
The development of engineered or modified autologous stem cells is an effective strategy to improve the efficacy of stem cell therapy.In this study,the stemness and functionality of adipose stem cells derived from typ...The development of engineered or modified autologous stem cells is an effective strategy to improve the efficacy of stem cell therapy.In this study,the stemness and functionality of adipose stem cells derived from type 1 diabetic donors(T1DM-ASC)were enhanced by treatment with Cu(II)-baicalein microflowers(Cu-MON).After treatment with Cu-MON,T1DM-ASC showed enhanced expression of the genes involved in the cytokine-cytokine receptor interaction pathway and increased cytokine secretion.Among the top 13 differentially expressed genes between T1DM-ASC and Cu-MON-treated T1DM-ASC(CMTA),some genes were also expressed in HUVEC,Myoblast,Myofibroblast,and Vascular Smooth Muscle cells,inferring the common role of these cell types.In vivo experiments showed that CMTA had the same therapeutic effect as adipose-derived stem cells from non-diabetic donors(ND-ASC)at a 15%cell dose,greatly reducing the treatment cost.Taken together,these findings suggest that Cu-MON promoted angiogenesis by promoting the stemness and functionality of T1DM-ASC and influencing multiple overall repair processes,including paracrine effects.展开更多
Although several synthetic hydrogels with defined stiffness have been developed to facilitate the proliferation and maintenance of human pluripotent stem cells(hPSCs),the influence of biochemical cues in lineage-speci...Although several synthetic hydrogels with defined stiffness have been developed to facilitate the proliferation and maintenance of human pluripotent stem cells(hPSCs),the influence of biochemical cues in lineage-specific differentiation and functional cluster formation has been rarely reported.Here,we present the application of Supragel,a supramolecular hydrogel formed by synthesized biotinylated peptides,for islet-like cluster differentiation.We observed that Supragel,with a peptide concentration of 5 mg/mL promoted spontaneous hPSCs formation into uniform clusters,which is mainly attributable to a supporting stiffness of∼1.5 kPa as provided by the Supragel matrix.Supragel was also found to interact with the hPSCs and facilitate endodermal and subsequent insulin-secreting cell differentiation,partially through its components:the sequences of RGD and YIGSR that interacts with cell membrane molecules of integrin receptor.Compared to Matrigel and suspension culturing conditions,more efficient differentiation of the hPSCs was also observed at the stages 3 and 4,as well as the final stage toward generation of insulin-secreting cells.This could be explained by 1)suitable average size of the hPSCs clusters cultured on Supragel;2)appropriate level of cell adhesive sites provided by Supragel during differentiation.It is worth noting that the Supragel culture system was more tolerance in terms of the initial seeding densities and less demanding,since a standard static cell culture condition was sufficient for the entire differentiation process.Our observations demonstrate a positive role of Supragel for hPSCs differentiation into islet-like cells,with additional potential in facilitating germ layer differentiation.展开更多
Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological status.Although a broad spectrum...Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological status.Although a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly characterized.An immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this need.Here,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory factors.To fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant.展开更多
Brain-specific serine/threonine-protein kinase 2(BRSK2)plays critical roles in insulin secretion andβ-cell biology.However,whether BRSK2 is associated with human type 2 diabetes mellitus(T2DM)has not been determined....Brain-specific serine/threonine-protein kinase 2(BRSK2)plays critical roles in insulin secretion andβ-cell biology.However,whether BRSK2 is associated with human type 2 diabetes mellitus(T2DM)has not been determined.Here,we report that BRSK2 genetic variants are closely related to worsening glucose metabolism due to hyperinsulinemia and insulin resistance in the Chinese population.BRSK2 protein levels are significantly elevated inβcells from T2DM patients and high-fat diet(HFD)-fed mice due to enhanced protein stability.Mice with inducibleβ-cell-specific Brsk2 knockout(βKO)exhibit normal metabolism with a high potential for insulin secretion under chow-diet conditions.Moreover,βKO mice are protected from HFD-induced hyperinsulinemia,obesity,insulin resistance,and glucose intolerance.Conversely,gain-of-function BRSK2 in matureβcells reversibly triggers hyperglycemia due toβ-cell hypersecretion-coupled insulin resistance.Mechanistically,BRSK2 senses lipid signals and induces basal insulin secretion in a kinase-dependent manner.The enhanced basal insulin secretion drives insulin resistance andβ-cell exhaustion and thus the onset of T2DM in mice fed an HFD or with gain-of-function BRSK2 inβcells.These findings reveal that BRSK2 links hyperinsulinemia to systematic insulin resistance via interplay betweenβcells and insulin-sensitive tissues in the populations carrying human genetic variants or under nutrient-overload conditions.展开更多
Compared with patients who undergo renal and islet transplantation sequentially,simultaneous omentum intraomental bio-scaf-fold islet-kidney transplantation in patients with type 1 diabetes complicated by renal failur...Compared with patients who undergo renal and islet transplantation sequentially,simultaneous omentum intraomental bio-scaf-fold islet-kidney transplantation in patients with type 1 diabetes complicated by renal failure has the advantages of donor homolo-gation,less trauma,lower cost,and easier acceptance by patients.Omentum intraomental bio-scaffold islet has been gradually applied in clinical practice,and rare clinical complications have been reported.Here we report a case of abdominal abscess associated with extended-spectrum β-lactamase in a patient who underwent simultaneous omentum intraomental bio-scaffold islet-kidney transplantation;the islet grafts remained partially functional after appropriate anti-infective treatment.展开更多
Breast cancer has become the most common malignant tumor worldwide.However,the survival rate of breast cancer patients in China is 8%lower compared to that in European and American countries.Insufficient screen-ing co...Breast cancer has become the most common malignant tumor worldwide.However,the survival rate of breast cancer patients in China is 8%lower compared to that in European and American countries.Insufficient screen-ing coverage and low rate of early detection are key problems.Therefore,it is imperative to develop a set of guidelines for breast cancer screening,early diagnosis,and treatment strategies suitable for Chinese women.The National Health Commission,the National Cancer Center,and the National Cancer Quality Control Center col-lectively organized a committee of specialists with multidisciplinary backgrounds in breast surgery,oncology,radiotherapy,diagnostic imaging,ultrasound,pathology,epidemiology,and health economics.The committee collectively published"China Breast Cancer Screening,Early Diagnosis and Treatment Specification",in which the committee outlined a set of strategies of breast cancer screening,early diagnosis,and treatment suitable for China’s national conditions.The strategies were formulated based on clinical experience in breast cancer preven-tion and treatment,characteristics of breast cancer patients in China,and socioeconomic conditions.The purpose of this article is to provide an interpretation of the above guidelines as a reference for breast cancer screening.展开更多
Purpose:Breast cancer is now the most common malignant tumor worldwide.About one-fourth of female cancer patients all over the world sufer from breast cancer.And about one in six female cancer deaths worldwide is caus...Purpose:Breast cancer is now the most common malignant tumor worldwide.About one-fourth of female cancer patients all over the world sufer from breast cancer.And about one in six female cancer deaths worldwide is caused by breast cancer.In terms of absolute numbers of cases and deaths,China ranks frst in the world.The CACA Guidelines for Holistic Integrative Management of Breast Cancer were edited to help improve the diagnosis and comprehensive treatment in China.Methods:The Grading of Recommendations Assessment,Development and Evaluation(GRADE)was used to classify evidence and consensus.Results:The CACA Guidelines for Holistic Integrative Management of Breast Cancer include the epidemiology of breast cancer,breast cancer screening,breast cancer diagnosis,early breast cancer treatment,advanced breast cancer treatment,follow-up,rehabilitation,and traditional Chinese medicine treatment of breast cancer patients.Conclusion:We to standardize the diagnosis and treatment of breast cancer in China through the formulation of the CACA Guidelines.展开更多
Background:The introductions of anti-human epidermal growth factor receptor-2(HER2)agents have significantly improved the treatment outcome of patients with HER2-positive breast cancer.BAT8001 is a novel antibodydrug ...Background:The introductions of anti-human epidermal growth factor receptor-2(HER2)agents have significantly improved the treatment outcome of patients with HER2-positive breast cancer.BAT8001 is a novel antibodydrug conjugate targeting human epidermal growth factor receptor-2(HER2)-expressing cells composed of a trastuzumab biosimilar linked to the drug-linker Batansine.This dose-escalation,phase I study was designed to assess the safety,tolerability,pharmacokinetics,and preliminary anti-tumor activity of BAT8001 in patients with HER2-positive locally advanced or metastatic breast cancer.Methods:This trial was conducted in subjects with histologically confirmed HER2-positive breast cancer(having evaluable lesions and an Eastern Cooperative Oncology Group performance status of 0 or 1)using a 3+3 design of escalating BAT8001 doses.Patients received BAT8001 intravenously in a 21-day cycle,with dose escalation in 5 cohorts:1.2,2.4,3.6,4.8,and 6.0 mg/kg.The primary objective was to evaluate the safety and tolerability of BAT8001.Preliminary activity of BAT8001 was also assessed as a secondary objective.Results:Between March 2017 to May 2018,29 HER2-positive breast cancer patients were enrolled.The observed dose-limiting toxicities were grade 4 thrombocytopenia and grade 3 elevated transaminase.The maximum tolerated dose was determined to be 3.6 mg/kg.Grade 3 or greater adverse events(AEs)occurred in 14(48.3%)of 29 patients,including thrombocytopenia in 12(41.4%)patients,aspartate aminotransferase increased in 4(13.8%)patients,γ-glutamyl transferase increased in 2(6.9%)patients,alanine aminotransferase increased in 2(6.9%)patients,diarrhea in 2(6.9%)patients.Objective response was observed in 12(41.4%,95%confidence interval[CI]=23.5%-61.1%)and disease control(including patients achieving objective response and stable disease)was observed in 24(82.8%,95%CI=64.2%-94.2%)patients.Conclusions:BAT8001 demonstrated favorable safety profiles,with promising anti-tumor activity in patients with HER2-positive locally advanced or metastatic breast cancer.BAT8001 has the potential to provide a new therapeutic option in patients with metastatic HER2-positive breast cancer.展开更多
A new method was developed in this study for producing a clear-sky Landsat composite for cropland from cloud-contaminated Landsat images acquired in a short time period.It used Thiel–Sen regression to normalize all L...A new method was developed in this study for producing a clear-sky Landsat composite for cropland from cloud-contaminated Landsat images acquired in a short time period.It used Thiel–Sen regression to normalize all Landsat scenes to a MODIS image to make all Landsat images radiometrically consistent and comparable.Pixel selection criteria combining the modified maximum vegetation index and the modified minimum visible reflectance selection methods were designed to enhance the pixel selection of land/water over cloud/shadow in the image compositing.The advantages of the method include(1)avoiding complicated atmospheric corrections but with reliable surface reflectance results,(2)being insensitive to errors induced by image coregistration uncertainties between Landsat and MODIS images,(3)avoiding the lack of samples for the regression analysis using the full Landsat scenes(rather than overlay regions),and(4)enhancing cloud/shadow detection.The composite image has MODIS-like surface reflectance,thus making MODIS algorithms applicable for retrieving biophysical parameters.The method was automatically implemented on a set of 13 cloud-contaminated(>39%)Landsat-7(Scan-Line CorrectorOff)and Landsat-8 scenes acquired during peak growing season in a crop region of Manitoba,Canada.The result was a 95.8%cloud-free image.The method can also substantially increase the usage of cloudcontaminated Landsat data.展开更多
Background:Real-world data of the CM regimen[cyclophosphamide(CTX)plus methotrexate(MTX)]in metronomic pattern for advanced breast cancer is limited to small-sample or retrospective studies.This study was aimed to det...Background:Real-world data of the CM regimen[cyclophosphamide(CTX)plus methotrexate(MTX)]in metronomic pattern for advanced breast cancer is limited to small-sample or retrospective studies.This study was aimed to determine the effectiveness and safety of CM regimen in treating advanced breast cancer and to identify which patients are most likely to benefit from metronomic CM regimen.Methods:Patients with advanced breast cancer who received the metronomic CM regimen at least once between January 2009 and February 2019 in Sun Yat-sen University Cancer Center were included.Clinicopathological characteristics were collected.Overall survival(OS)and progression-free survival(PFS)were assessed using Kaplan-Meier estimates.Characteristics between patients with PFS<6 months and≥6 months were compared using the Chi-square test.Univariate and multivariate Cox regression model was used to estimate the prognostic factors for PFS and OS.Results:A total of 186 patients were included.The median age and follow-up were 49 years and 13.3 months,respectively.Over 50%of the patients were estrogen receptor/progesterone receptor-positive,and 60.8%had been heavily treated(≥3 lines).The objective response rate was 3.8%,the disease control rate at 12 weeks was 41.4%,and the clinical benefit rate at 24 weeks was 31.2%(58/186).The median PFS was 4.0 months[95%confidence interval(CI):3.6-4.7 months],the median duration of clinical benefit was 9.5 months(95%CI:8.2-10.8 months),and the median OS was 26.8 months(95%CI:20.9-37.7 months).Multivariate analysis for PFS revealed the CM regimen as maintenance therapy and no liver metastasis as favorable prognostic factors.Furthermore,patients without liver metastasis were more likely to have a PFS over 6 months than those with liver involvement(P=0.022).Liver,lymph node,and brain metastases were unfavorable prognostic factors for OS.The CM regimen was well-tolerated without newly reported adverse events.Conclusions:The CM regimen was effective in selected patients.In clinical practice,it would be better used as maintenance therapy and in patients without liver metastasis.Further follow-up investigation should be performed to examine its effect when used in combination with other treatments and determine predictive biomarkers.展开更多
Dear Editor,Breast cancer(BrC)is the most common cancer in women.Triple negative BrC(TNBC)is the subtype with highly aggressive clinical behaviors and heterogeneity.Metastasis is the leading cause of TNBC-related deat...Dear Editor,Breast cancer(BrC)is the most common cancer in women.Triple negative BrC(TNBC)is the subtype with highly aggressive clinical behaviors and heterogeneity.Metastasis is the leading cause of TNBC-related deaths,but its mechanism is not well-understood.Apart from PIK3CA,TP53,and PTEN,few recurrent mutations have been identified in TNBC so far,suggesting that TNBC phenotype could be driven by nongenetic alterations such as aberrant expression of oncogenes.展开更多
Purpose:Chemotherapy-induced nail pigmentation is a common adverse efect,but prospective studies focussing on its onset,recovery,and severity are few.We aim to evaluate the pattern of chemotherapy-induced nail pigment...Purpose:Chemotherapy-induced nail pigmentation is a common adverse efect,but prospective studies focussing on its onset,recovery,and severity are few.We aim to evaluate the pattern of chemotherapy-induced nail pigmentation in early-stage breast cancer patients by calculating the comprehensive score based on hyperpigmentation area and color depth of the nail plate.Methods:This prospective,observational study was conducted between February 2019 and December 2019.Early-stage breast cancer patients scheduled to receive anthracyclines combined with cyclophosphamide or taxanecontaining regimens were enrolled.The clinicopathologic characteristics and treatment protocols were collected.The onset,patterns,and duration of nail changes were photographed and recorded regularly.Results:A total of 90 patients were enrolled.The most common nail change was nail pigmentation(n=81,90.0%),followed by onycholysis(n=39,43.3%),Beau’s lines(n=19,21.1%),Mees’lines(n=16,17.8%),Muehrcke’s lines(n=7,7.8%),and hemorrhage(n=1,1.1%).Forty-four(48.9%)patients developed severe nail pigmentation.The median onset time of nail pigmentation was 37 days after the initiation of chemotherapy.At the latest follow-up,55(67.9%)patients achieved remission of melanonychia with the median recovery time of 118 days.The median duration of nail pigmentation was 214 days.Conclusion:Our study revealed the specifc pattern of chemotherapy-induced nail pigmentation,which onsets early and recovers slowly with a high incidence of severe nail pigmentation,in early-stage breast cancer patients.The results provide reference for further intervention studies.Trial Registration:ClinicalTrials.gov Identifer:NCT04215744.Registered 30 December 2019—Retrospectively registered.展开更多
文摘Objective： The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conventional second-line chemotherapy, Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemotherapy may improve both disease free survival （DFS） and overall survival （OS） of naive patients, but its role in the second-line therapy for relapsed non-Hodgkin＇s Lymphoma （NHL） remains to be defined, This study aimed to evaluate the efficacy of rituximab-containing salvage regimens for relapsed or refractory NHL, and observe the toxicities. Methods： The clinical data of 54 patients, who were with relapsed or refractory NHL and treated in the Cancer Center of Sun Yat-sen University, were analyzed retrospectively, Of the 54 patients, 29 were man, 25 were women, with a median age of 52.5 years old （range 18 to 75）; 50 patients （92.6%） scored 0-1 for the ECOG performance status; for second-line international prognostic index （slPI）, 21 （38.9%） scored 0-1,30 （55.6%） scored 2 to 3, and 3 （5.6%） scored 4-5; 40 cases were diffuse large B-cell lymphoma （DLBCL）, accounting for 74.1% of all subtypes, Rituximab was administered intravenously at a dose of 375 mg/m^2 at the day before each chemotherapy cycle, The second or third-line salvage regimens included EPOCH, CHOP, DHAP, DICE, IVAC, IMVP-16 and FND, Results： Of the 54 patients, 49 received retuximab-containing salvage regimens, The objective response rate of the 45 evaluable cases was 68,8%, with a complete remission （CR） rate of 37.7%; 3 patients achieved CR after radiotherapy following rituximab-based regimens and 3 achieved CR after autologous hematopoietic stem cell transplantation, The most frequent adverse events were leucopenia, nausea and alopecia. The addition of rituximab to chemotherapy only elevated the occurrence of mild infusion-related reactions, such as chills, fever and pruritus. The median follow-up time was 18 months （range 2-86 months）; 5 patients were lost, 24 were dead （23 died of lymphoma, and 1 died of severe hepatitis）, the other patients remained alive. The median survival time was 32 months （range 2-86 months, 95% confidential interval 16-48 months）. The 1-, 2- and 3-year OS rates were 70.6%, 53,6% and 41,5%, respectively, The median TTP was 6 months （range 0-52 months）, The median PFS was 10 months （range 0-47 months, 95% CI 0-26 months）, The 1- and 2-year PFS were 49,3% and 41,3%. Conclusion： Rituximab-containing salvage regimens are effective and well tolerated therapy for patients with relapsed or refractory B-cell NHL, even those were extensively treated.
基金supported Chicago Diahetes Project(CDP)National Institutes of Health(NIH)ROl DK091526,R25 DK105924-01Natural ScienceFoundation of Tianjin,China(13JCYBJC42600)
基金National Natural Science Foundation of China(82072080)CAMS Innovation Fund for Medical Sciences(2023-I2M-2-008,2022-I2M-3-002,2021-12M-1-058)+1 种基金supported by Special Program for High-Tech Leader&Teams of Tianjin GovernmentTianjin innovation Promotion Plan Key Innovation Team of Immunreactive Biomaterials.
文摘The development of engineered or modified autologous stem cells is an effective strategy to improve the efficacy of stem cell therapy.In this study,the stemness and functionality of adipose stem cells derived from type 1 diabetic donors(T1DM-ASC)were enhanced by treatment with Cu(II)-baicalein microflowers(Cu-MON).After treatment with Cu-MON,T1DM-ASC showed enhanced expression of the genes involved in the cytokine-cytokine receptor interaction pathway and increased cytokine secretion.Among the top 13 differentially expressed genes between T1DM-ASC and Cu-MON-treated T1DM-ASC(CMTA),some genes were also expressed in HUVEC,Myoblast,Myofibroblast,and Vascular Smooth Muscle cells,inferring the common role of these cell types.In vivo experiments showed that CMTA had the same therapeutic effect as adipose-derived stem cells from non-diabetic donors(ND-ASC)at a 15%cell dose,greatly reducing the treatment cost.Taken together,these findings suggest that Cu-MON promoted angiogenesis by promoting the stemness and functionality of T1DM-ASC and influencing multiple overall repair processes,including paracrine effects.
基金National Key Technologies Research and Development Program of China(2020YFA0803701)National Natural Science Foundation of China(81921004,T2122019)CAMS Innovation Fund for Medical Sciences(2021–12M-1-052).
文摘Although several synthetic hydrogels with defined stiffness have been developed to facilitate the proliferation and maintenance of human pluripotent stem cells(hPSCs),the influence of biochemical cues in lineage-specific differentiation and functional cluster formation has been rarely reported.Here,we present the application of Supragel,a supramolecular hydrogel formed by synthesized biotinylated peptides,for islet-like cluster differentiation.We observed that Supragel,with a peptide concentration of 5 mg/mL promoted spontaneous hPSCs formation into uniform clusters,which is mainly attributable to a supporting stiffness of∼1.5 kPa as provided by the Supragel matrix.Supragel was also found to interact with the hPSCs and facilitate endodermal and subsequent insulin-secreting cell differentiation,partially through its components:the sequences of RGD and YIGSR that interacts with cell membrane molecules of integrin receptor.Compared to Matrigel and suspension culturing conditions,more efficient differentiation of the hPSCs was also observed at the stages 3 and 4,as well as the final stage toward generation of insulin-secreting cells.This could be explained by 1)suitable average size of the hPSCs clusters cultured on Supragel;2)appropriate level of cell adhesive sites provided by Supragel during differentiation.It is worth noting that the Supragel culture system was more tolerance in terms of the initial seeding densities and less demanding,since a standard static cell culture condition was sufficient for the entire differentiation process.Our observations demonstrate a positive role of Supragel for hPSCs differentiation into islet-like cells,with additional potential in facilitating germ layer differentiation.
基金supported by the National Natural Science Foundation of China(31730036,31871380,31871382,31930055,31930058,32000500,32022034,32030033,32070730,32130046,3217050247,32150005,32200595,32222024,81730019,81730022,81830014,81921006,81925005,81970426,81971301,81971312,82030041,82061160495,82070805,82071595,82090020,82100841,82120108009,82122024,82125002,82125011,82125012,82130045,82171284,82173061,82173398,82225007,82225015,82225017,82225018,82230047,82230088,82271600,91949106,91949201,92049116,92049302,92049304,92149303,92149306,92157202,92168201,92169102,92249301,92268201)the National Key Research and Development Program of China(2018YFA0800700,2018YFC2000100,2018YFC2000102,2018YFC2002003,2019YFA0110900,2019YFA0801703,2019YFA0801903,2019YFA0802202,2019YFA0904800,2020YFA0113400,2020YFA0803401,2020YFA0804000,2020YFC2002900,2020YFC2008000,2020YFE0202200,2021YFA0804900,2021YFA1100103,2021YFA1100900,2021YFE0114200,2021ZD0202400,2022YFA0806001,2022YFA0806002,2022YFA0806600,2022YFA1103200,2022YFA1103601,2022YFA1103701,2022YFA1103800,2022YFA1103801,2022YFA1104100,2022YFA1104904,2022YFA1303000,2022YFC2009900,2022YFC2502401,2022YFC3602400,2022YFE0118000,2022ZD0213200)+14 种基金the Strategic Priority Research Program of the Chinese Academy of Sciences(XDA16030302,XDB39000000,XDB39030600)the Youth Innovation Promotion Association of Chinese Academy of Sciences(2020085,2021080)CAS Project for Young Scientists in Basic Research(YSBR-076)the Program of the Beijing Natural Science Foundation(JQ20031)Clinical Research Operating Fund of Central High level hospitals(2022-PUMCHE-001)CAMS Innovation Fund for Medical Sciences(CIFMS)(2022-I2M1-004)Talent Program of the Chinese Academy of Medical Science(2022RC310-10)Research Funds from Health@Inno HK Program launched by Innovation Technology Commission of the Hong Kong Special Administrative Region,Guangdong Basic and Applied Basic Research Foundation(2020B1515020044)Guangzhou Planned Project of Science and Technology(202002020039)the Major Technology Innovation of Hubei Province(2019ACA141)the Science and Technology Major Project of Hunan Provincial Science and Technology Department(2021SK1010)Shanghai Municipal Science and Technology Major Project(2017SHZDZX01)the Natural Science Foundation of Sichuan Province(2023NSFSC0003)Yunnan Fundamental Research Project(202201AS070080)the State Key Laboratory of Membrane Biology。
文摘Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological status.Although a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly characterized.An immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this need.Here,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory factors.To fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant.
基金supported by research grants from the National Natural Science Foundation of China(81420108007 and 81830024 to X.H.,82270844,82070843,and 81870531 to Y.Zhu).
文摘Brain-specific serine/threonine-protein kinase 2(BRSK2)plays critical roles in insulin secretion andβ-cell biology.However,whether BRSK2 is associated with human type 2 diabetes mellitus(T2DM)has not been determined.Here,we report that BRSK2 genetic variants are closely related to worsening glucose metabolism due to hyperinsulinemia and insulin resistance in the Chinese population.BRSK2 protein levels are significantly elevated inβcells from T2DM patients and high-fat diet(HFD)-fed mice due to enhanced protein stability.Mice with inducibleβ-cell-specific Brsk2 knockout(βKO)exhibit normal metabolism with a high potential for insulin secretion under chow-diet conditions.Moreover,βKO mice are protected from HFD-induced hyperinsulinemia,obesity,insulin resistance,and glucose intolerance.Conversely,gain-of-function BRSK2 in matureβcells reversibly triggers hyperglycemia due toβ-cell hypersecretion-coupled insulin resistance.Mechanistically,BRSK2 senses lipid signals and induces basal insulin secretion in a kinase-dependent manner.The enhanced basal insulin secretion drives insulin resistance andβ-cell exhaustion and thus the onset of T2DM in mice fed an HFD or with gain-of-function BRSK2 inβcells.These findings reveal that BRSK2 links hyperinsulinemia to systematic insulin resistance via interplay betweenβcells and insulin-sensitive tissues in the populations carrying human genetic variants or under nutrient-overload conditions.
基金partially supported by the National Key Research and Development Program of China(2020YFA0803704)National Natural Science Found of China(82070805).
文摘Compared with patients who undergo renal and islet transplantation sequentially,simultaneous omentum intraomental bio-scaf-fold islet-kidney transplantation in patients with type 1 diabetes complicated by renal failure has the advantages of donor homolo-gation,less trauma,lower cost,and easier acceptance by patients.Omentum intraomental bio-scaffold islet has been gradually applied in clinical practice,and rare clinical complications have been reported.Here we report a case of abdominal abscess associated with extended-spectrum β-lactamase in a patient who underwent simultaneous omentum intraomental bio-scaffold islet-kidney transplantation;the islet grafts remained partially functional after appropriate anti-infective treatment.
文摘Breast cancer has become the most common malignant tumor worldwide.However,the survival rate of breast cancer patients in China is 8%lower compared to that in European and American countries.Insufficient screen-ing coverage and low rate of early detection are key problems.Therefore,it is imperative to develop a set of guidelines for breast cancer screening,early diagnosis,and treatment strategies suitable for Chinese women.The National Health Commission,the National Cancer Center,and the National Cancer Quality Control Center col-lectively organized a committee of specialists with multidisciplinary backgrounds in breast surgery,oncology,radiotherapy,diagnostic imaging,ultrasound,pathology,epidemiology,and health economics.The committee collectively published"China Breast Cancer Screening,Early Diagnosis and Treatment Specification",in which the committee outlined a set of strategies of breast cancer screening,early diagnosis,and treatment suitable for China’s national conditions.The strategies were formulated based on clinical experience in breast cancer preven-tion and treatment,characteristics of breast cancer patients in China,and socioeconomic conditions.The purpose of this article is to provide an interpretation of the above guidelines as a reference for breast cancer screening.
基金Department of Breast Surgery,Harbin Medical University Cancer Hospital,Harbin,China。
文摘Purpose:Breast cancer is now the most common malignant tumor worldwide.About one-fourth of female cancer patients all over the world sufer from breast cancer.And about one in six female cancer deaths worldwide is caused by breast cancer.In terms of absolute numbers of cases and deaths,China ranks frst in the world.The CACA Guidelines for Holistic Integrative Management of Breast Cancer were edited to help improve the diagnosis and comprehensive treatment in China.Methods:The Grading of Recommendations Assessment,Development and Evaluation(GRADE)was used to classify evidence and consensus.Results:The CACA Guidelines for Holistic Integrative Management of Breast Cancer include the epidemiology of breast cancer,breast cancer screening,breast cancer diagnosis,early breast cancer treatment,advanced breast cancer treatment,follow-up,rehabilitation,and traditional Chinese medicine treatment of breast cancer patients.Conclusion:We to standardize the diagnosis and treatment of breast cancer in China through the formulation of the CACA Guidelines.
基金This study was supported by the Natural Science Foundation of Guangdong Province(2020A1515010105)Joint Fund of the National Natural Science Foundation of China and Natural Science Foundation of Guangdong Province(U1601224).
文摘Background:The introductions of anti-human epidermal growth factor receptor-2(HER2)agents have significantly improved the treatment outcome of patients with HER2-positive breast cancer.BAT8001 is a novel antibodydrug conjugate targeting human epidermal growth factor receptor-2(HER2)-expressing cells composed of a trastuzumab biosimilar linked to the drug-linker Batansine.This dose-escalation,phase I study was designed to assess the safety,tolerability,pharmacokinetics,and preliminary anti-tumor activity of BAT8001 in patients with HER2-positive locally advanced or metastatic breast cancer.Methods:This trial was conducted in subjects with histologically confirmed HER2-positive breast cancer(having evaluable lesions and an Eastern Cooperative Oncology Group performance status of 0 or 1)using a 3+3 design of escalating BAT8001 doses.Patients received BAT8001 intravenously in a 21-day cycle,with dose escalation in 5 cohorts:1.2,2.4,3.6,4.8,and 6.0 mg/kg.The primary objective was to evaluate the safety and tolerability of BAT8001.Preliminary activity of BAT8001 was also assessed as a secondary objective.Results:Between March 2017 to May 2018,29 HER2-positive breast cancer patients were enrolled.The observed dose-limiting toxicities were grade 4 thrombocytopenia and grade 3 elevated transaminase.The maximum tolerated dose was determined to be 3.6 mg/kg.Grade 3 or greater adverse events(AEs)occurred in 14(48.3%)of 29 patients,including thrombocytopenia in 12(41.4%)patients,aspartate aminotransferase increased in 4(13.8%)patients,γ-glutamyl transferase increased in 2(6.9%)patients,alanine aminotransferase increased in 2(6.9%)patients,diarrhea in 2(6.9%)patients.Objective response was observed in 12(41.4%,95%confidence interval[CI]=23.5%-61.1%)and disease control(including patients achieving objective response and stable disease)was observed in 24(82.8%,95%CI=64.2%-94.2%)patients.Conclusions:BAT8001 demonstrated favorable safety profiles,with promising anti-tumor activity in patients with HER2-positive locally advanced or metastatic breast cancer.BAT8001 has the potential to provide a new therapeutic option in patients with metastatic HER2-positive breast cancer.
基金This work was supported by the Long Term Satellite Data Records Project and Groundwater Geoscience Program of NRCan.
文摘A new method was developed in this study for producing a clear-sky Landsat composite for cropland from cloud-contaminated Landsat images acquired in a short time period.It used Thiel–Sen regression to normalize all Landsat scenes to a MODIS image to make all Landsat images radiometrically consistent and comparable.Pixel selection criteria combining the modified maximum vegetation index and the modified minimum visible reflectance selection methods were designed to enhance the pixel selection of land/water over cloud/shadow in the image compositing.The advantages of the method include(1)avoiding complicated atmospheric corrections but with reliable surface reflectance results,(2)being insensitive to errors induced by image coregistration uncertainties between Landsat and MODIS images,(3)avoiding the lack of samples for the regression analysis using the full Landsat scenes(rather than overlay regions),and(4)enhancing cloud/shadow detection.The composite image has MODIS-like surface reflectance,thus making MODIS algorithms applicable for retrieving biophysical parameters.The method was automatically implemented on a set of 13 cloud-contaminated(>39%)Landsat-7(Scan-Line CorrectorOff)and Landsat-8 scenes acquired during peak growing season in a crop region of Manitoba,Canada.The result was a 95.8%cloud-free image.The method can also substantially increase the usage of cloudcontaminated Landsat data.
基金Joint Fund of National Natural Science Foundation of China,Grant/Award Number:U1601224Research Data Deposit,Grant/Award Number:RDDA2020001375。
文摘Background:Real-world data of the CM regimen[cyclophosphamide(CTX)plus methotrexate(MTX)]in metronomic pattern for advanced breast cancer is limited to small-sample or retrospective studies.This study was aimed to determine the effectiveness and safety of CM regimen in treating advanced breast cancer and to identify which patients are most likely to benefit from metronomic CM regimen.Methods:Patients with advanced breast cancer who received the metronomic CM regimen at least once between January 2009 and February 2019 in Sun Yat-sen University Cancer Center were included.Clinicopathological characteristics were collected.Overall survival(OS)and progression-free survival(PFS)were assessed using Kaplan-Meier estimates.Characteristics between patients with PFS<6 months and≥6 months were compared using the Chi-square test.Univariate and multivariate Cox regression model was used to estimate the prognostic factors for PFS and OS.Results:A total of 186 patients were included.The median age and follow-up were 49 years and 13.3 months,respectively.Over 50%of the patients were estrogen receptor/progesterone receptor-positive,and 60.8%had been heavily treated(≥3 lines).The objective response rate was 3.8%,the disease control rate at 12 weeks was 41.4%,and the clinical benefit rate at 24 weeks was 31.2%(58/186).The median PFS was 4.0 months[95%confidence interval(CI):3.6-4.7 months],the median duration of clinical benefit was 9.5 months(95%CI:8.2-10.8 months),and the median OS was 26.8 months(95%CI:20.9-37.7 months).Multivariate analysis for PFS revealed the CM regimen as maintenance therapy and no liver metastasis as favorable prognostic factors.Furthermore,patients without liver metastasis were more likely to have a PFS over 6 months than those with liver involvement(P=0.022).Liver,lymph node,and brain metastases were unfavorable prognostic factors for OS.The CM regimen was well-tolerated without newly reported adverse events.Conclusions:The CM regimen was effective in selected patients.In clinical practice,it would be better used as maintenance therapy and in patients without liver metastasis.Further follow-up investigation should be performed to examine its effect when used in combination with other treatments and determine predictive biomarkers.
基金supported by the National Natural Science Foundation of China(NSFC:U1601224,81972569,81602313,81772925,and 81702761)Natural Science Foundation of Guangdong Province(2019A1515011945 and 2017A030313489)Guangdong Science and Technology Foundation(2014A020212384).
文摘Dear Editor,Breast cancer(BrC)is the most common cancer in women.Triple negative BrC(TNBC)is the subtype with highly aggressive clinical behaviors and heterogeneity.Metastasis is the leading cause of TNBC-related deaths,but its mechanism is not well-understood.Apart from PIK3CA,TP53,and PTEN,few recurrent mutations have been identified in TNBC so far,suggesting that TNBC phenotype could be driven by nongenetic alterations such as aberrant expression of oncogenes.
文摘Purpose:Chemotherapy-induced nail pigmentation is a common adverse efect,but prospective studies focussing on its onset,recovery,and severity are few.We aim to evaluate the pattern of chemotherapy-induced nail pigmentation in early-stage breast cancer patients by calculating the comprehensive score based on hyperpigmentation area and color depth of the nail plate.Methods:This prospective,observational study was conducted between February 2019 and December 2019.Early-stage breast cancer patients scheduled to receive anthracyclines combined with cyclophosphamide or taxanecontaining regimens were enrolled.The clinicopathologic characteristics and treatment protocols were collected.The onset,patterns,and duration of nail changes were photographed and recorded regularly.Results:A total of 90 patients were enrolled.The most common nail change was nail pigmentation(n=81,90.0%),followed by onycholysis(n=39,43.3%),Beau’s lines(n=19,21.1%),Mees’lines(n=16,17.8%),Muehrcke’s lines(n=7,7.8%),and hemorrhage(n=1,1.1%).Forty-four(48.9%)patients developed severe nail pigmentation.The median onset time of nail pigmentation was 37 days after the initiation of chemotherapy.At the latest follow-up,55(67.9%)patients achieved remission of melanonychia with the median recovery time of 118 days.The median duration of nail pigmentation was 214 days.Conclusion:Our study revealed the specifc pattern of chemotherapy-induced nail pigmentation,which onsets early and recovers slowly with a high incidence of severe nail pigmentation,in early-stage breast cancer patients.The results provide reference for further intervention studies.Trial Registration:ClinicalTrials.gov Identifer:NCT04215744.Registered 30 December 2019—Retrospectively registered.
